All have drawn fire: from politicians who complained about skipped side-effect disclosures, from activists who saw body-shaming propaganda and from doctors worried about malnourishment
The GLP-1 receptor agonist market features a variety of approved and investigational products, including short-acting agonists like exenatide and lixisenatide, long-acting options such as semaglutide, dulaglutide, and liraglutide, as well as oral formulations like oral semaglutide (Rybelsus)
Tirzepatide and health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 randomized trial
Be informed, because they will impact society, including how your healthcare and tax dollars are spent
Others notice continued appetite suppression for as long as they stay on the medication
After 56 weeks: Placebo group lost 1.2% of body weight Recommended dose (7.5/46 mg) group lost 7.8% of body weight Top dose (15/92 mg) group lost 9.8% of body weight The EQUIP trial enrolled 1,267 adults with class II and III obesity (BMI 35+)
